Wyeth Applauds Governments' Decision to Fund Pneumococcal Vaccine

Wyeth Applauds Governments' Decision to Fund Pneumococcal Vaccine

February 12, 2007

    COLLEGEVILLE, Pa., Feb. 12 /Xinhua-PRNewswire/ -- Wyeth
Pharmaceuticals, a division of Wyeth (NYSE: WYE), welcomes
the decision by donor countries to focus on the importance
of pneumococcal disease and to launch a pilot Advanced
Market Commitment, which will help to bring the
pneumococcal conjugate vaccine to developing countries.

    "This financial pledge brings much needed
attention to the global burden of pneumococcal
disease," says Bernard Poussot, President, Chief
Operating Officer and Vice Chairman, Wyeth.  "We join
the International Federation of Pharmaceutical
Manufacturers and Associations and the global community in
commending the donor countries, and look forward to
cooperating with international partners with the goal of
helping to protect children in developing countries against
the potentially devastating consequences of pneumococcal
disease."

    Wyeth is committed to helping to protect infants and
young children against pneumococcal disease and currently
markets the only pneumococcal conjugate vaccine,
PREVENAR(TM), Pneumococcal Saccharide Conjugated Vaccine,
Adsorbed, which has been incorporated into many childhood
immunization programs around the world and has had a
significant public health impact. 

    Recently, the World Health Organization (WHO) Strategic
Advisory Group of Experts (SAGE), advocated for priority
inclusion of PREVENAR in national immunization programs
around the world.   SAGE recommended that the vaccine be
incorporated into immunization programs now, in view of the
demonstrated vaccine efficacy and high disease burden, to
help substantially reduce mortality and morbidity. 

    In addition, Wyeth is now developing a 13-valent
pneumococcal conjugate vaccine that targets additional
serotypes.  This investigational vaccine is currently
undergoing clinical development and would potentially offer
broader coverage against pneumococcal disease.
    
    About Pneumococcal Disease

    Pneumococcal disease is caused by the bacterium S.
pneumoniae, and describes a group of illnesses, including
bacteremia/sepsis, meningitis, pneumonia and otitis media. 
Pneumococcal disease affects both children and adults and is
a major cause of death and illness worldwide.  The WHO
estimates that pneumococcal disease results in up to one
million deaths each year in children less than 5 years of
age worldwide.  Further, according to WHO, pneumococcal
disease is the number one vaccine-preventable cause of
death in children less than 5 years of age worldwide.

    Wyeth Pharmaceuticals

    Wyeth Pharmaceuticals, a division of Wyeth, has leading
products in the areas of women's health care, infectious
disease, gastrointestinal health, central nervous system,
inflammation, transplantation, hemophilia, oncology,
vaccines and nutritional products.  

    Wyeth is one of the world's largest research-driven
pharmaceutical and health care products companies.  It is a
leader in the discovery, development, manufacturing and
marketing of pharmaceuticals, vaccines, biotechnology
products and non-prescription medicines that improve the
quality of life for people worldwide.  The Company's major
divisions include Wyeth Pharmaceuticals, Wyeth Consumer
Healthcare and Fort Dodge Animal Health.

    The statements in this press release that are not
historical facts are forward-looking statements based on
current expectations of future events and are subject to
risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such
statements.  These risks and uncertainties include risks
associated with the inherent uncertainty of the timing and
success of product research, development and
commercialization (including with respect to our pipeline
products), drug pricing and payment for our products by
government and third party-payors, manufacturing, data
generated on the safety and efficacy of our products,
economic conditions including interest and currency
exchange rate fluctuations, changes in generally accepted
accounting principles, the impact of competitive or generic
products, trade buying patterns, global business operations,
product liability and other types of litigation, the impact
of legislation and regulatory compliance, intellectual
property rights, strategic relationships with third
parties, environmental liabilities, and other risks and
uncertainties, including those detailed from time to time
in our periodic reports filed with the Securities and
Exchange Commission, including our current reports on Form
8-K, quarterly reports on Form 10-Q and annual report on
Form 10-K, particularly the discussion under the caption
"Item 1A, Risk Factors."  We assume no obligation
to publicly update any forward-looking statements, whether
as a result of new information, future developments or
otherwise.



    For more information, please contact:

     Natalie de Vane
     Wyeth Pharmaceuticals
     Tel:  [phone]

     Valerie Bomberger
     Wyeth Pharmaceuticals 
     Tel:  [phone]

     Investor Contact: 

     Justin Victoria, Wyeth
     Tel:  [phone]


SOURCE  Wyeth Pharmaceuticals